Istradefylline for OFF Episodes in Parkinson’s Disease: A US Perspective of Common Clinical Scenarios

References

• LeWitt PA, Chaudhuri KR. Unmet needs in Parkinson disease: motor and non-motor. Parkinsonism Relat Disord. 2020;80(Suppl 1):S7–S12. doi:10.1016/j.parkreldis.2020.09.024
   PubMed Web of Science ®Google Scholar
• Bjornestad A, Forsaa EB, Pedersen KF, Tysnes OB, Larsen JP, Alves G. Risk and course of motor complications in a population-based incident Parkinson’s disease cohort. Parkinsonism Relat Disord. 2016;22:48–53. doi:10.1016/j.parkreldis.2015.11.007
   PubMed Web of Science ®Google Scholar
• Scott NW, Macleod AD, Counsell CE. Motor complications in an incident Parkinson’s disease cohort. Eur J Neurol. 2016;23(2):304–312. doi:10.1111/ene.12751
   PubMed Web of Science ®Google Scholar
• Kim H-J, Mason S, Foltynie T, Winder-Rhodes S, Barker RA, Williams-Gray CH. Motor complications in Parkinson’s disease: 13-year follow-up of the CamPaIGN cohort. Mov Disorders. 2020;35(1):185–190. doi:10.1002/mds.27882
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Shimoda S, Origasa H. Long-term treatment of Parkinson’s disease with levodopa and other adjunctive drugs. J Neural Transm. 2018;125(1):35–43. doi:10.1007/s00702-016-1671-x
   PubMed Web of Science ®Google Scholar
• Poewe W, Stocchi F, Arkadir D, et al. Subcutaneous levodopa infusion for Parkinson’s disease: one-year data from the open-label BeyoND study. Mov Disord. 2021;36(11):2687–2692. doi:10.1002/mds.28758
   PubMed Web of Science ®Google Scholar
• Antonini A, Isaias IU, Canesi M, et al. Duodenal levodopa infusion for advanced Parkinson’s disease: 12-month treatment outcome. Mov Disord. 2007;22(8):1145–1149. doi:10.1002/mds.21500
   PubMed Web of Science ®Google Scholar
• Stowe R, Ives N, Clarke CE, et al. Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson’s disease. Mov Disord. 2011;26(4):587–598. doi:10.1002/mds.23517
   PubMed Web of Science ®Google Scholar
• Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P. Long-term efficacy of opicapone in fluctuating Parkinson’s disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions. Eur J Neurol. 2019;26(7):953–960. doi:10.1111/ene.13914
   PubMed Web of Science ®Google Scholar
• Giossi R, Carrara F, Mazzari M, et al. Overall efficacy and safety of safinamide in Parkinson’s disease: a systematic review and a meta-analysis. Clin Drug Invest. 2021;41(4):321–339. doi:10.1007/s40261-021-01011-y
   PubMed Web of Science ®Google Scholar
• Hauser RA, Lytle J, Formella AE, Tanner CM. Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson’s disease. NPJ Parkinsons Dis. 2022;8(1):29. doi:10.1038/s41531-022-00291-1
   PubMed Web of Science ®Google Scholar
• Chou KL. Adverse events from the treatment of Parkinson’s disease. Neurol Clin. 2008;26(3Suppl):S65–83,vi. doi:10.1016/j.ncl.2008.05.003
   PubMed Web of Science ®Google Scholar
• Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology. 2009;72(21 Suppl 4):S1–136. doi:10.1212/WNL.0b013e3181a1d44c
   PubMed Web of Science ®Google Scholar
• Gonzalez-Latapi P, Bhowmick SS, Saranza G, Fox SH. Non-dopaminergic treatments for motor control in Parkinson’s disease: an update. CNS Drugs. 2020;34:1025–1044. doi:10.1007/s40263-020-00754-0
   PubMed Web of Science ®Google Scholar
• Hung AY, Schwarzschild MA. Treatment of Parkinson’s disease: what’s in the non-dopaminergic pipeline? Neurotherapeutics. 2014;11(1):34–46. doi:10.1007/s13311-013-0239-9
   PubMed Web of Science ®Google Scholar
• Riederer P, Gerlach M, Muller T, Reichmann H. Relating mode of action to clinical practice: dopaminergic agents in Parkinson’s disease. Parkinsonism Relat Disord. 2007;13(8):466–479. doi:10.1016/j.parkreldis.2007.06.015
   PubMed Web of Science ®Google Scholar
• Fuxe K, Ferré S, Genedani S, Franco R, Agnati LF. Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function. Physiol Behav. 2007;92(1–2):210–217. doi:10.1016/j.physbeh.2007.05.034
   PubMed Web of Science ®Google Scholar
• Schiffmann SN, Fisone G, Moresco R, Cunha RA, Ferre S. Adenosine A2A receptors and basal ganglia physiology. Prog Neurobiol. 2007;83(5):277–292. doi:10.1016/j.pneurobio.2007.05.001
   PubMed Web of Science ®Google Scholar
• Jarvis MF, Williams M. Direct autoradiographic localization of adenosine A2 receptors in the rat brain using the A2-selective agonist, [3H]CGS 21680. Eur J Pharmacol. 1989;168(2):243–246. doi:10.1016/0014-2999(89)90571-2
   PubMed Web of Science ®Google Scholar
• Rosin DL, Robeva A, Woodard RL, Guyenet PG, Linden J. Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system. J Comp Neurol. 1998;401(2):163–186. doi:10.1002/(SICI)1096-9861(19981116)401:2<163::AID-CNE2>3.0.CO;2-D
   PubMed Web of Science ®Google Scholar
• Svenningsson P, Hall H, Sedvall G, Fredholm BB. Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study. Synapse. 1997;27(4):322–335. doi:10.1002/(SICI)1098-2396(199712)27:4<322::AID-SYN6>3.0.CO;2-E
   PubMed Web of Science ®Google Scholar
• Ishiwata K, Mishina M, Kimura Y, Oda K, Sasaki T, Ishii K. First visualization of adenosine A2A receptors in the human brain by positron emission tomography with [11C]TMSX. Synapse. 2005;55(2):133–136. doi:10.1002/syn.20099
   PubMed Web of Science ®Google Scholar
• Mori A. How do adenosine A(2A) receptors regulate motor function? Parkinsonism Relat Disord. 2020;80(Suppl 1):S13–s20. doi:10.1016/j.parkreldis.2020.09.025
   PubMed Web of Science ®Google Scholar
• Saki M, Yamada K, Koshimura E, Sasaki K, Kanda T. In vitro pharmacological profile of the A2A receptor antagonist istradefylline. Naunyn Schmiedebergs Arch Pharmacol. 2013;386(11):963–972. doi:10.1007/s00210-013-0897-5
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Guttman M, Tetrud JW, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson’s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol. 2008;63(3):295–302. doi:10.1002/ana.21315
   PubMed Web of Science ®Google Scholar
• Stacy M, Silver D, Mendis T, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology. 2008;70(23):2233–2240. doi:10.1212/01.wnl.0000313834.22171.17
   PubMed Web of Science ®Google Scholar
• Hauser RA, Shulman LM, Trugman JM, et al. Study of istradefylline in patients with Parkinson’s disease on levodopa with motor fluctuations. Mov Disord. 2008;23(15):2177–2185. doi:10.1002/mds.22095
   PubMed Web of Science ®Google Scholar
• Pourcher E, Fernandez HH, Stacy M, Mori A, Ballerini R, Chaikin P. Istradefylline for Parkinson’s disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Parkinsonism Relat Disord. 2012;18(2):178–184. doi:10.1016/j.parkreldis.2011.09.023
   PubMed Web of Science ®Google Scholar
• Kyowa Hakko Kirin UK L. A 16-week, double-blind, placebo-controlled, randomised, parallel-group, multicentre, international study to evaluate the efficacy and safety of 40 mg/day KW-6002 (istradefylline) and that of entacapone versus placebo as treatment for Parkinson’s disease in patients with motor response complications on levodopa therapy; 2005. Available from: https://clinicaltrials.gov/ct2/show/study/NCT00199394. Accessed June 29, 2022.
   Google Scholar
• Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M; Japanese Istradefylline Study Group. Clinical efficacy of istradefylline (KW-6002) in Parkinson’s disease: a randomized, controlled study. Mov Disord. 2010;25(10):1437–1443. doi:10.1002/mds.23107
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Kondo T; Japanese Istradefylline Study Group. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease. Mov Disord. 2013;28(8):1138–1141. doi:10.1002/mds.25418
   PubMed Web of Science ®Google Scholar
• Kyowa Hakko Kirin Pharma I. A phase 3, 12-week, double-blind, placebo-controlled, randomized, multicenter study to evaluate the efficacy of oral istradefylline 20 and 40 mg/day as treatment for subjects with moderate to severe Parkinson’s disease; 2016. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01968031. Accessed June 29, 2022.
   Google Scholar
• LeWitt PA, Aradi SD, Hauser RA, Rascol O. The challenge of developing adenosine A(2A) antagonists for Parkinson disease: istradefylline, preladenant, and tozadenant. Parkinsonism Relat Disord. 2020;80(Suppl 1):S54–s63. doi:10.1016/j.parkreldis.2020.10.027
   PubMed Web of Science ®Google Scholar
• Hauser RA, Hattori N, Fernandez H, et al. Efficacy of istradefylline, an adenosine A2A receptor antagonist, as adjunctive therapy to levodopa in Parkinson’s disease: a pooled analysis of 8 phase 2b/3 trials. J Parkinsons Dis. 2021;11(4):1663–1675. doi:10.3233/JPD-212672
   PubMedGoogle Scholar
• Jenner P, Mori A, Aradi SD, Hauser RA. Istradefylline - a first generation adenosine A2A antagonist for the treatment of Parkinson’s disease. Expert Rev Neurother. 2021;21(3):317–333. doi:10.1080/14737175.2021.1880896
   PubMed Web of Science ®Google Scholar
• Takahashi M, Fujita M, Asai N, Saki M, Mori A. Safety and effectiveness of istradefylline in patients with Parkinson’s disease: interim analysis of a post-marketing surveillance study in Japan. Expert Opin Pharmacother. 2018;19(15):1635–1642. doi:10.1080/14656566.2018.1518433
   PubMed Web of Science ®Google Scholar
• EMA Nouryant Assessment report. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/nouryant. Accessed June 29, 2022.
   Google Scholar
• Center for Drug Evaluation and Research. Summary review: 022075Orig1s000. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022075Orig1s000SumR.pdf. Accessed June 29, 2022.
   Google Scholar
• Center for Drug Evaluation and Research. Clinical review: NDA 022075. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022075Orig1s000MedR.pdf. Accessed June 29, 2022.
   Google Scholar
• NOURIANZ™ (istradefylline) tablets, for oral use. US Prescribing information. Available from: https://www.nourianz.com/assets/pdf/nourianz-full-prescribing-information.pdf. Accessed June 29, 2022.
   Google Scholar
• Olanow CW, Kieburtz K, Rascol O, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord. 2013;28(8):1064–1071. doi:10.1002/mds.25364
   PubMed Web of Science ®Google Scholar
• Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson’s disease. Mov Disord. 2005;20(11):1502–1507. doi:10.1002/mds.20602
   PubMed Web of Science ®Google Scholar
• Stocchi F. The levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerations. Expert Opin Pharmacother. 2006;7(10):1399–1407. doi:10.1517/14656566.7.10.1399
   PubMedGoogle Scholar
• Stocchi F, Jenner P, Obeso JA. When do levodopa motor fluctuations first appear in Parkinson’s disease? Eur Neurol. 2010;63(5):257–266. doi:10.1159/000300647
   PubMed Web of Science ®Google Scholar
• Lewitt P, Hattori N, Mori A, et al. Efficacy of istradefylline, an A2A receptor antagonist, when added to levodopa (LD) and other medications for Parkinson’s disease (PD) [abstract]. Mov Disord. 2019;34(suppl 2):e54.
   Google Scholar
• Kaakkola S. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson’s disease. Int Rev Neurobiol. 2010;95:207–225.
   PubMed Web of Science ®Google Scholar
• Hattori N, Nomura M, Salzman P, et al. Frequency of dyskinesia as a function of baseline dyskinesia in patients with Parkinson’s disease treated with istradefylline, an adenosine A2A receptor antagonist. Mov Disord Clin Pract. 2020;7(S1):S13–S111.
   Google Scholar
• Bibbiani F, Oh JD, Petzer JP, et al. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson’s disease. Exp Neurol. 2003;184(1):285–294. doi:10.1016/S0014-4886(03)00250-4
   PubMed Web of Science ®Google Scholar
• Kanda T, Jackson MJ, Smith LA, et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol. 1998;43(4):507–513. doi:10.1002/ana.410430415
   PubMed Web of Science ®Google Scholar
• Kanda T, Jackson MJ, Smith LA, et al. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol. 2000;162(2):321–327. doi:10.1006/exnr.2000.7350
   PubMed Web of Science ®Google Scholar
• Grondin R, Bedard PJ, Hadj Tahar A, Gregoire L, Mori A, Kase H. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology. 1999;52(8):1673–1677. doi:10.1212/WNL.52.8.1673
   PubMed Web of Science ®Google Scholar
• Elmer L, Toyama K, Parno J, Braccia D, Ristuccia R, Mori A. Safety and efficacy of istradefylline, an adenosine A2A receptor antagonist, as a function of baseline dyskinesia (BL-dyskinesia) in Parkinson’s disease (PD): a pooled analysis of 4 studies [abstract]. Mov Disord. 2020;35(suppl 1):S393–S394.
   Google Scholar
• Zuzuárregui JRP, During EH. Sleep issues in Parkinson’s disease and their management. Neurotherapeutics. 2020;17(4):1480–1494. doi:10.1007/s13311-020-00938-y
   PubMed Web of Science ®Google Scholar
• Avorn J, Schneeweiss S, Sudarsky LR, et al. Sudden uncontrollable somnolence and medication use in parkinson disease. Arch Neurol. 2005;62(8):1242–1248. doi:10.1001/archneur.62.8.1242
   PubMedGoogle Scholar
• Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH. A reassessment of risks and benefits of dopamine agonists in Parkinson’s disease. Lancet Neurol. 2009;8(10):929–937. doi:10.1016/S1474-4422(09)70225-X
   PubMed Web of Science ®Google Scholar
• Bares M, Kanovský P, Rektor I. Excessive daytime sleepiness and ‘sleep attacks’ induced by entacapone. Fundam Clin Pharmacol. 2003;17(1):113–116. doi:10.1046/j.1472-8206.2003.00120.x
   PubMed Web of Science ®Google Scholar
• ONGENTYS (opicapone) capsules, for oral use. Full prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212489s000lbl.pdf. Accessed June 29, 2022.
   Google Scholar
• STALEVO (carbidopa, levodopa and entacapone) tablets, for oral use. Full prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021485s042lbl.pdf. Accessed June 29, 2022.
   Google Scholar
• Mirapex® (pramipexole dihydrochloride). Full prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020667s014s017s018lbl.pdf. Accessed June 29, 2022.
   Google Scholar
• Jenner P, Mori A, Kanda T. Can adenosine A2A receptor antagonists be used to treat cognitive impairment, depression or excessive sleepiness in Parkinson’s disease? Parkinsonism Relat Disord. 2020;80(Suppl 1):S28–S36. doi:10.1016/j.parkreldis.2020.09.022
   PubMed Web of Science ®Google Scholar
• Lazarus M, Oishi Y, Bjorness TE, Greene RW. Gating and the need for sleep: dissociable effects of adenosine A(1) and A(2A) receptors. Front Neurosci. 2019;13:740. doi:10.3389/fnins.2019.00740
   PubMed Web of Science ®Google Scholar
• Huang ZL, Zhang Z, Qu WM. Roles of adenosine and its receptors in sleep-wake regulation. Int Rev Neurobiol. 2014;119:349–371.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Miyamoto M, Miyamoto T, et al. Istradefylline improves daytime sleepiness in patients with Parkinson’s disease: an open-label, 3-month study. J Neurol Sci. 2017;380:230–233. doi:10.1016/j.jns.2017.07.045
   PubMed Web of Science ®Google Scholar
• Matsuura K, Kajikawa H, Tabei KI, et al. The effectiveness of istradefylline for the treatment of gait deficits and sleepiness in patients with Parkinson’s disease. Neurosci Lett. 2018;662:158–161. doi:10.1016/j.neulet.2017.10.018
   PubMed Web of Science ®Google Scholar
• Baumann CR. Epidemiology, diagnosis and differential diagnosis in Parkinson’s disease tremor. Parkinsonism Relat Disord. 2012;18:S90–S92. doi:10.1016/S1353-8020(11)70029-3
   PubMed Web of Science ®Google Scholar
• Pagan F, Parno J, Ristuccia R, Mori A, Istradefylline T-Y-Y. Effects on tremor dominant (TD) and postural instability and gait difficulty (PIGD) motor subtypes (4540). Neurology. 2021;96(15 Supplement):4540.
   Web of Science ®Google Scholar
• Beiske AG, Loge JH, Hjermstad MJ, Svensson E. Fatigue in Parkinson’s disease: prevalence and associated factors. Mov Disord. 2010;25(14):2456–2460. doi:10.1002/mds.23372
   PubMed Web of Science ®Google Scholar
• Stocchi F, Abbruzzese G, Ceravolo R, et al. Prevalence of fatigue in Parkinson disease and its clinical correlates. Neurology. 2014;83(3):215–220. doi:10.1212/WNL.0000000000000587
   PubMed Web of Science ®Google Scholar
• Oved D, Ziv I, Treves TA, Paleacu D, Melamed E, Djaldetti R. Effect of dopamine agonists on fatigue and somnolence in Parkinson’s disease. Mov Disord. 2006;21(8):1257–1261. doi:10.1002/mds.20929
   PubMed Web of Science ®Google Scholar
• Stocchi F. Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson’s disease. Eur J Neurol. 2014;21(2):357–360. doi:10.1111/ene.12205
   PubMed Web of Science ®Google Scholar
• Lim TT, Kluger BM, Rodriguez RL, et al. Rasagiline for the symptomatic treatment of fatigue in Parkinson’s disease. Mov Disord. 2015;30(13):1825–1830. doi:10.1002/mds.26429
   PubMed Web of Science ®Google Scholar
• Abe K, Fujita M, Yoshikawa H. Effectiveness of istradefylline for fatigue and quality of life in Parkinson’s disease patients’ and of their caregivers’. Adv Parkinson Dis. 2016;5:24–28. doi:10.4236/apd.2016.52004
   Google Scholar
• Ito H, Kamei T. Adenosine A2A receptor antagonist istradefylline might have efficacy to fatigue and depression in some patients of Parkinson’s disease [abstract]. Mov Disord. 2016;31(suppl 2):S626–S626.
   Google Scholar
• Shimo Y, Maeda T, Chiu S-W, et al. Influence of istradefylline on non-motor symptoms of Parkinson’s disease: a subanalysis of a 1-year observational study in Japan (J-FIRST). Parkinsonism Relat Disord. 2021;91:115–120. doi:10.1016/j.parkreldis.2021.09.015
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Day GS, Smith DB, et al. Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary: a report of the AAN guideline subcommittee. Neurology. 2021;97(20):942–957. doi:10.1212/WNL.0000000000012868
   PubMed Web of Science ®Google Scholar
• REQUIP® (ropinirole hydrochloride) tablets. Prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020658s018s020s021lbl.pdf. Accessed June 29, 2022.
   Google Scholar
• Neupro (Rotigotine Transdermal System). Full prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s001lbl.pdf. Accessed June 29, 2022.
   Google Scholar
• Senard JM, Raï S, Lapeyre-Mestre M, et al. Prevalence of orthostatic hypotension in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;63(5):584–589. doi:10.1136/jnnp.63.5.584
   PubMed Web of Science ®Google Scholar
• Ha AD, Brown CH, York MK, Jankovic J. The prevalence of symptomatic orthostatic hypotension in patients with Parkinson’s disease and atypical parkinsonism. Parkinsonism Relat Disord. 2011;17(8):625–628. doi:10.1016/j.parkreldis.2011.05.020
   PubMed Web of Science ®Google Scholar
• Isaacson SH, Skettini J. Neurogenic orthostatic hypotension in Parkinson’s disease: evaluation, management, and emerging role of droxidopa. Vasc Health Risk Manag. 2014;10:169–176. doi:10.2147/VHRM.S53983
   PubMedGoogle Scholar
• Kujawa K, Leurgans S, Raman R, Blasucci L, Goetz CG. Acute orthostatic hypotension when starting dopamine agonists in Parkinson’s disease. Arch Neurol. 2000;57(10):1461–1463. doi:10.1001/archneur.57.10.1461
   PubMedGoogle Scholar
• Lang AE. Acute orthostatic hypotension when starting dopamine agonist therapy in Parkinson disease: the role of domperidone therapy. Arch Neurol. 2001;58(5):835. doi:10.1001/archneur.58.5.835
   PubMedGoogle Scholar
• Senard JM, Brefel-Courbon C, Rascol O, Montastruc JL. Orthostatic hypotension in patients with Parkinson’s disease: pathophysiology and management. Drugs Aging. 2001;18(7):495–505. doi:10.2165/00002512-200118070-00003
   PubMed Web of Science ®Google Scholar
• Suzuki K, Miyamoto T, Miyamoto M, Uchiyama T, Hirata K. Could istradefylline be a treatment option for postural abnormalities in mid-stage Parkinson’s disease? J Neurol Sci. 2018;385:131–133. doi:10.1016/j.jns.2017.12.027
   PubMed Web of Science ®Google Scholar
• Fujioka S, Yoshida R, Nose K, et al. A new therapeutic strategy with istradefylline for postural deformities in Parkinson’s disease. Neurol Neurochir Pol. 2019;53(4):291–295. doi:10.5603/PJNNS.a2019.0036
   PubMed Web of Science ®Google Scholar
• Iijima M, Orimo S, Terashi H, et al. Efficacy of istradefylline for gait disorders with freezing of gait in Parkinson’s disease: a single-arm, open-label, prospective, multicenter study. Expert Opin Pharmacother. 2019;20(11):1405–1411. doi:10.1080/14656566.2019.1614167
   PubMed Web of Science ®Google Scholar
• Kitta T, Yabe I, Kanno Y, et al. Long-term outcome of adenosine A2A receptor antagonist on lower urinary tract symptoms in male Parkinson disease patients. Clin Neuropharmacol. 2018;41(3):98–102. doi:10.1097/WNF.0000000000000281
   PubMed Web of Science ®Google Scholar
• Nagayama H, Kano O, Murakami H, et al. Effect of istradefylline on mood disorders in Parkinson’s disease. J Neurol Sci. 2019;396:78–83. doi:10.1016/j.jns.2018.11.005
   PubMed Web of Science ®Google Scholar